# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 16, "Ann Intern Med .", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasJournal> \"Ann Intern Med .\"."
1, PublicationYear, 17, 21, "2008", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasPublicationYear> \"2008\"."
97, Title, 53, 219, "Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control : a randomized trial .", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasTitle> \"Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control : a randomized trial .\"."
52171, LisproProtamine, 65, 97, "neutral protamine lispro insulin", "", 
2, InsulinGlargine, 101, 117, "insulin glargine", "", 
94, Type2Diabetes, 126, 141, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_110371> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
4, Precondition, 155, 196, "patients with suboptimal glycemic control", "", "<http://ctro/data#Population_110389> <http://ctro/data#hasPrecondition> \"patients with suboptimal glycemic control\"."
5, Randomized, 201, 211, "randomized", "", "<http://ctro/data#ClinicalTrial_110371> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
6, Author, 220, 230, "Esposito K", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasAuthor> \"Esposito K\"."
7, Author, 239, 248, "Ciotola M", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasAuthor> \"Ciotola M\"."
8, Author, 251, 262, "Maiorino MI", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasAuthor> \"Maiorino MI\"."
9, Author, 265, 276, "Gualdiero R", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasAuthor> \"Gualdiero R\"."
10, Author, 279, 289, "Schisano B", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasAuthor> \"Schisano B\"."
11, Author, 292, 302, "Ceriello A", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasAuthor> \"Ceriello A\"."
12, Author, 305, 315, "Beneduce F", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasAuthor> \"Beneduce F\"."
13, Author, 318, 325, "Feola G", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasAuthor> \"Feola G\"."
14, Author, 328, 339, "Giugliano D", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasAuthor> \"Giugliano D\"."
15, Italy, 446, 451, "Italy", "", "<http://ctro/data#Population_110389> <http://ctro/data#hasCountry> <http://ctro/data#Italy>."
16, Insulin, 686, 693, "insulin", "", 
108, Bedtime, 697, 704, "bedtime", "", 
19, Precondition, 742, 816, "patients with type 2 diabetes that is poorly controlled with oral regimens", "", "<http://ctro/data#Population_110389> <http://ctro/data#hasPrecondition> \"patients with type 2 diabetes that is poorly controlled with oral regimens\"."
17, Type2Diabetes, 756, 771, "type 2 diabetes", "", 
52176, LisproProtamine, 819, 843, "Neutral protamine lispro", "", 
52177, LisproProtamine, 846, 849, "NPL", "", 
20, Insulin, 852, 859, "insulin", "", 
21, Hypoglycemia, 926, 938, "hypoglycemic", "", 
114, Insulin, 959, 993, "neutral protamine Hagedorn insulin", "", 
125, ObjectiveDescription, 1008, 1224, "To compare the clinical efficacy and safety of bedtime NPL insulin or insulin glargine in patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea .", "", "<http://ctro/data#ClinicalTrial_110371> <http://ctro/data#hasObjectiveDescription> \"To compare the clinical efficacy and safety of bedtime NPL insulin or insulin glargine in patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea .\"."
118, Bedtime, 1055, 1062, "bedtime", "", 
52179, LisproProtamine, 1063, 1074, "NPL insulin", "", 
22, InsulinGlargine, 1078, 1094, "insulin glargine", "", 
26, Precondition, 1098, 1222, "patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea", "", "<http://ctro/data#Population_110389> <http://ctro/data#hasPrecondition> \"patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea\"."
23, Type2Diabetes, 1112, 1127, "type 2 diabetes", "", 
24, Metformin, 1196, 1205, "metformin", "", 
25, Sulfonylureas, 1210, 1222, "sulfonylurea", "", 
27, OpenLabel, 1234, 1246, "Open - label", "", "<http://ctro/data#ClinicalTrial_110371> <http://ctro/data#hasCTDesign> <http://ctro/data#OpenLabel>."
28, Randomized, 1249, 1259, "randomized", "", 
29, Italy, 1375, 1380, "Italy", "", 
30, NumberPatientsCT, 1394, 1397, "116", "", "<http://ctro/data#ClinicalTrial_110371> <http://ctro/data#hasNumberPatientsCT> \"116\"."
137, Precondition, 1398, 1548, "adults receiving stable doses of metformin plus sulfonylurea for longer than 90 days with hemoglobin A ( 1c ) ( HbA ( 1c ) ) levels of 7 . 5 % to 10 %", "", "<http://ctro/data#Population_110389> <http://ctro/data#hasPrecondition> \"adults receiving stable doses of metformin plus sulfonylurea for longer than 90 days with hemoglobin A ( 1c ) ( HbA ( 1c ) ) levels of 7 . 5 % to 10 %\"."
31, Metformin, 1431, 1440, "metformin", "", 
32, Sulfonylureas, 1446, 1458, "sulfonylurea", "", 
33, Duration, 1463, 1482, "longer than 90 days", "", 
34, HbA1c, 1488, 1507, "hemoglobin A ( 1c )", "", 
131, HbA1c, 1510, 1520, "HbA ( 1c )", "", 
36, Percentage, 1539, 1540, "%", "", 
37, Percentage, 1547, 1548, "%", "", 
119911, Precondition, 1553, 1634, "fasting plasma glucose levels of 6 . 7 mmol / L or greater ( > or = 120 mg / dL )", "", "<http://ctro/data#Population_110389> <http://ctro/data#hasPrecondition> \"fasting plasma glucose levels of 6 . 7 mmol / L or greater ( > or = 120 mg / dL )\"."
38, FastingPlasmaGlucose, 1553, 1575, "fasting plasma glucose", "", 
39, Millimoles_per_litre, 1592, 1600, "mmol / L", "", 
40, Mg_per_deciliter, 1625, 1632, "mg / dL", "", 
42, DoseValue, 1652, 1654, "10", "", "<http://ctro/data#Medication_110467> <http://ctro/data#hasDoseValue> \"10\". <http://ctro/data#Medication_110474> <http://ctro/data#hasDoseValue> \"10\"."
226, Int_Unit, 1655, 1657, "IU", "", "<http://ctro/data#Medication_110467> <http://ctro/data#hasDoseUnit> <http://ctro/data#Int_Unit>. <http://ctro/data#Medication_110474> <http://ctro/data#hasDoseUnit> <http://ctro/data#Int_Unit>."
52178, LisproProtamine, 1661, 1672, "NPL insulin", "", "<http://ctro/data#Medication_110467> <http://ctro/data#hasDrug> <http://ctro/data#LisproProtamine>."
43, InsulinGlargine, 1676, 1692, "insulin glargine", "", "<http://ctro/data#Medication_110474> <http://ctro/data#hasDrug> <http://ctro/data#InsulinGlargine>."
144, SubcutaneousInjection, 1693, 1716, "injected subcutaneously", "", "<http://ctro/data#Medication_110467> <http://ctro/data#hasDeliveryMethod> <http://ctro/data#SubcutaneousInjection>. <http://ctro/data#Medication_110474> <http://ctro/data#hasDeliveryMethod> <http://ctro/data#SubcutaneousInjection>."
145, Bedtime, 1720, 1727, "bedtime", "", "<http://ctro/data#Intervention_110449> <http://ctro/data#hasRelativeFreqTime> <http://ctro/data#Bedtime>. <http://ctro/data#Intervention_110455> <http://ctro/data#hasRelativeFreqTime> <http://ctro/data#Bedtime>."
46, Frequency, 1733, 1739, "weekly", "", 
102222, DoseDescription, 1740, 1867, "dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens", "", "<http://ctro/data#Medication_110467> <http://ctro/data#hasDoseDescription> \"dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens\". <http://ctro/data#Medication_110474> <http://ctro/data#hasDoseDescription> \"dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens\"."
146, FastingPlasmaGlucose_target, 1766, 1831, "fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL )", "", 
147, Millimoles_per_litre, 1805, 1813, "mmol / L", "", 
148, Mg_per_deciliter, 1822, 1829, "mg / dL", "", 
45, OralAntidiabeticAgent, 1854, 1867, "oral regimens", "", "<http://ctro/data#Medication_110481> <http://ctro/data#hasDrug> <http://ctro/data#OralAntidiabeticAgent>."
149, Bedtime, 1889, 1898, "nighttime", "", 
47, Sulfonylureas, 1899, 1911, "sulfonylurea", "", 
48, Metformin, 1946, 1955, "metformin", "", 
49, HbA1c, 2007, 2017, "HbA ( 1c )", "", "<http://ctro/data#Endpoint_110401> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
230, TimePoint, 2030, 2038, "baseline", "", 
231, TimePoint, 2042, 2049, "week 36", "", "<http://ctro/data#Outcome_110488> <http://ctro/data#hasTimePoint> \"week 36\". <http://ctro/data#Outcome_110515> <http://ctro/data#hasTimePoint> \"week 36\". <http://ctro/data#Outcome_110551> <http://ctro/data#hasTimePoint> \"week 36\". <http://ctro/data#Outcome_110578> <http://ctro/data#hasTimePoint> \"week 36\". <http://ctro/data#Outcome_110619> <http://ctro/data#hasTimePoint> \"week 36\". <http://ctro/data#Outcome_110646> <http://ctro/data#hasTimePoint> \"week 36\". <http://ctro/data#Outcome_110687> <http://ctro/data#hasTimePoint> \"week 36\". <http://ctro/data#Outcome_110714> <http://ctro/data#hasTimePoint> \"week 36\"."
50, HbA1c_target, 2076, 2107, "HbA ( 1c ) levels less than 7 %", "", "<http://ctro/data#Endpoint_110406> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
154, Percentage, 2106, 2107, "%", "", "<http://ctro/data#Endpoint_110406> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
51, Hypoglycemia, 2126, 2147, "hypoglycemic episodes", "", 
232, InsulinDose, 2150, 2162, "insulin dose", "", 
233, Glucose, 2182, 2195, "glucose level", "", 
52, BodyWeight, 2202, 2213, "body weight", "", 
53, Insulin, 2317, 2324, "insulin", "", 
234, TimePoint, 2332, 2339, "week 36", "", 
54, HbA1c, 2367, 2377, "HbA ( 1c )", "", 
55, Reduction, 2414, 2420, "1 . 83", "", "<http://ctro/data#Outcome_110488> <http://ctro/data#hasChangeValue> \"1 . 83\"."
57, Percentage, 2421, 2422, "%", "", "<http://ctro/data#Endpoint_110401> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
56, Reduction, 2427, 2433, "1 . 89", "", "<http://ctro/data#Outcome_110515> <http://ctro/data#hasChangeValue> \"1 . 89\"."
58, Percentage, 2434, 2435, "%", "", 
52180, LisproProtamine, 2440, 2443, "NPL", "", 
60, InsulinGlargine, 2448, 2456, "glargine", "", 
52181, DiffGroupRelValue, 2514, 2520, "0 . 06", "", "<http://ctro/data#DiffBetweenGroups_110542> <http://ctro/data#hasDiffGroupRelValue> \"0 . 06\"."
63, ConfIntervalDiff, 2540, 2567, "95 % CI , - 0 . 1 to 0 . 15", "", "<http://ctro/data#DiffBetweenGroups_110542> <http://ctro/data#hasConfIntervalDiff> \"95 % CI , - 0 . 1 to 0 . 15\"."
65, HbA1c_target, 2641, 2681, "Hemoglobin A ( 1c ) levels less than 7 %", "", 
172, Percentage, 2680, 2681, "%", "", 
66, PercentageAffected, 2694, 2696, "62", "", "<http://ctro/data#Outcome_110551> <http://ctro/data#hasPercentageAffected> \"62\"."
52182, LisproProtamine, 2721, 2724, "NPL", "", 
67, PercentageAffected, 2729, 2731, "64", "", "<http://ctro/data#Outcome_110578> <http://ctro/data#hasPercentageAffected> \"64\". <http://ctro/data#Outcome_110646> <http://ctro/data#hasPercentageAffected> \"64\"."
68, InsulinGlargine, 2756, 2764, "glargine", "", 
81, DiffGroupRelValue, 2780, 2785, "2 . 0", "", "<http://ctro/data#DiffBetweenGroups_110605> <http://ctro/data#hasDiffGroupRelValue> \"2 . 0\". <http://ctro/data#DiffBetweenGroups_110673> <http://ctro/data#hasDiffGroupRelValue> \"2 . 0\"."
69, ConfIntervalDiff, 2806, 2827, "CI , - 1 . 1 to 5 . 0", "", "<http://ctro/data#DiffBetweenGroups_110605> <http://ctro/data#hasConfIntervalDiff> \"CI , - 1 . 1 to 5 . 0\". <http://ctro/data#DiffBetweenGroups_110673> <http://ctro/data#hasConfIntervalDiff> \"CI , - 1 . 1 to 5 . 0\"."
70, FastingPlasmaGlucose_target, 2852, 2924, "Fasting plasma glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL )", "", "<http://ctro/data#Endpoint_110614> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose_target>."
182, Millimoles_per_litre, 2898, 2906, "mmol / L", "", "<http://ctro/data#Endpoint_110614> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
183, Mg_per_deciliter, 2915, 2922, "mg / dL", "", 
71, PercentageAffected, 2937, 2939, "40", "", "<http://ctro/data#Outcome_110619> <http://ctro/data#hasPercentageAffected> \"40\"."
52183, LisproProtamine, 2964, 2967, "NPL", "", 
72, PercentageAffected, 2972, 2974, "41", "", 
73, InsulinGlargine, 2999, 3007, "glargine", "", 
82, DiffGroupRelValue, 3023, 3028, "1 . 0", "", 
74, ConfIntervalDiff, 3048, 3069, "CI , - 0 . 9 to 3 . 0", "", 
75, Hypoglycemia, 3098, 3110, "hypoglycemic", "", "<http://ctro/data#Endpoint_110682> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
76, PercentageAffected, 3129, 3131, "74", "", "<http://ctro/data#Outcome_110687> <http://ctro/data#hasPercentageAffected> \"74\"."
52184, LisproProtamine, 3156, 3159, "NPL", "", 
77, PercentageAffected, 3164, 3166, "67", "", "<http://ctro/data#Outcome_110714> <http://ctro/data#hasPercentageAffected> \"67\"."
78, InsulinGlargine, 3191, 3199, "glargine", "", 
79, DiffGroupRelValue, 3215, 3216, "7", "", "<http://ctro/data#DiffBetweenGroups_110741> <http://ctro/data#hasDiffGroupRelValue> \"7\"."
80, ConfIntervalDiff, 3237, 3251, "CI , - 5 to 13", "", "<http://ctro/data#DiffBetweenGroups_110741> <http://ctro/data#hasConfIntervalDiff> \"CI , - 5 to 13\"."
240, ObservedResult, 3276, 3383, "Continuous glucose level monitoring in the patients who had this measurement did not differ statistically .", "", "<http://ctro/data#Outcome_110755> <http://ctro/data#hasObservedResult> \"Continuous glucose level monitoring in the patients who had this measurement did not differ statistically .\"."
239, Glucose, 3287, 3294, "glucose", "", "<http://ctro/data#Glucose_110751> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Glucose>. <http://ctro/data#Endpoint_110750> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Glucose_110751>."
207, OpenLabel, 3411, 3422, "not blinded", "", 
83, Hypoglycemia, 3468, 3480, "hypoglycemic", "", 
241, Glucose, 3520, 3527, "glucose", "", 
213, ConclusionComment, 3577, 3725, "Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes .", "", "<http://ctro/data#ClinicalTrial_110371> <http://ctro/data#hasConclusionComment> \"Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes .\"."
52185, LisproProtamine, 3632, 3635, "NPL", "", 
84, InsulinGlargine, 3639, 3655, "glargine insulin", "", 
85, OralAntidiabeticAgent, 3659, 3672, "oral regimens", "", 
86, Type2Diabetes, 3708, 3723, "type 2 diabetes", "", 
88, Hypoglycemia, 3726, 3738, "Hypoglycemia", "", 
215, ConclusionComment, 3726, 3843, "Hypoglycemia was similar in the 2 groups , but sample size limited the ability to make a definite safety assessment .", "", "<http://ctro/data#ClinicalTrial_110371> <http://ctro/data#hasConclusionComment> \"Hypoglycemia was similar in the 2 groups , but sample size limited the ability to make a definite safety assessment .\"."
89, PMID, 3911, 3919, "18936501", "", "<http://ctro/data#Publication_110356> <http://ctro/data#hasPMID> \"18936501\"."
